The Way Forward
Harnessing the Power of Predictive Models
Though several states have recently passed legislation limiting co-pay accumulator programs, with more states expected to follow, the issue of accumulators is complex and the future far from predictable.
On this issue and on other drug matters, the pendulum of reform may continue to swing as costs are shifted back and forth among competing stakeholders.healthcare attorney John S. Linehan
RxCrossroads by McKesson urges Biopharma companies to act strategically now.
By maintaining a dialogue with patients, employers and providers and harnessing the power of machine learning-based predictive models to develop smarter, more flexible solutions, companies can meet this challenge head on.
Learn more about how RxCrossroads by McKesson is addressing the accumulator issue.
- Prescriber Targeting
- Accumulator Predictor Tool™
- PA Reach
- Adherence Impact
- Benefit Design Tool
- Cash Card Exclusion Logic
- Machine Learning & Trend Forecastings
- Accumulator Assessment Analysis
References
- “2018 and Beyond: Outlook and Turning Points.” Institute Report. IQVIA, March 13, 2018, https://www.iqvia.com/insights/the-iqvia-institute/reports/2018-and-beyond-outlook-and-turning-points.
- “2018 Drug Trend Report.” Express Scripts, Feb. 6, 2019, https://www.express-scripts.com/corporate/drug-trend-report.
- “Co-Pay Accumulator Programs: 2019 Update.” Access Market Intelligence, 2018, https://accessmarketintell.com/product/copay-accumulator-programs-2019-update/.
- “Copay Accumulator Programs: How they impact patients with complex and chronic conditions.” McKesson Corporation, 2018.
- Cohen, Robin A., Ph.D. et al. “Health Insurance Coverage: Early Release of Estimates from the National Health Interview Survey, January–March 2018.” U.S. Department of Health and Human Services, National Center for Health Statistics. Centers for Disease Control and Prevention, August 2018, https://www.cdc.gov/nchs/data/nhis/earlyrelease/Insur201808.pdf.
- Abdus, Salam, Ph.D., and Patricia S. Keenan, Ph.D. “Financial Burden of Employer-Sponsored High-Deductible Health Plans for Low-Income Adults With Chronic Health Conditions.” Journal of the American Medical Association. JAMA Internal Medicine, doi:10.1001/jamainternmed.2018.4706, https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2705692.
- RxCrossroads by McKesson proprietary research and data.
- “PBMs’ copay ‘accumulator’ programs are a rising threat to pharma’s support of patient reimbursement, says TrialCard.” Pharmaceutical Commerce, April 25, 2018, https://pharmaceuticalcommerce.com/brand-marketing-communications/pbms-copay-accumulator-programs-are-a-rising-threat-to-pharmas-support-of-patient-reimbursement-says-trialcard/.
- “Copay Accumulator Update: Widespread Adoption As Manufacturers and Maximizers Limit Patient Impact.” Drug Channels, Sept. 18, 2018, https://www.drugchannels.net/2018/09/copay-accumulator-update-widespread.html.
- Linehan, John S. “State legislatures spring ahead with restrictions on drug copay accumulators.” Managed Care, April 16, 2019, https://www.managedcaremag.com/voices/state-legislatures-spring-ahead-restrictions-drug-copay-accumulators.